Ibrahim Al-Zakwani

Prof. Dr. Ibrahim Al-Zakwani

Sultan Qaboos University, Muscat, Masqaţ, Oman

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2015 in European Journal of Heart Failure
Verified
Journal Article
Closed access
PDF file
KSKadhim Sulaiman
Kadhim Sulaiman
PPPrashanth Panduranga
Prashanth Panduranga
IAIbrahim Al-Zakwani
Ibrahim Al-Zakwani
AAAlawi A. Alsheikh-Ali
Alawi A. Alsheikh-Ali
KAKhalid F. AlHabib
Khalid F. AlHabib
HAHaitham Amin
Haitham Amin

16 January 2006 in Cost Effectiveness and Resource Allocation
Verified
Journal Article
Open access
PDF file
AOAlan K Oglesby
Alan K Oglesby
KSKristina Secnik
Kristina Secnik
JBJohn Barron
John Barron
IAIbrahim Al-Zakwani
Ibrahim Al-Zakwani
MLMaureen J Lage
Maureen J Lage
Background: The objective of this research is to quantify the association between direct medical costs attributable to type 2 diabetes and level of glycemic control. Methods: A longitudinal analysis using a large health plan administrative database was performed. The index date was defined as the first date of diabetes diagnosis and individuals had to have at least two HbA1c values post index date in order to be included in the analyses. A total of 10,780 individuals were included in the analyses. Individuals were stratified into groups of good (N = 6,069), fair (N = 3,586), and poor (N = 1,125) glycemic control based upon mean HbA1c values across the study period. Differences between HbA1c groups were analyzed using a generalized linear model (GLM), with differences between groups tested by utilizing z-statistics. The analyses allowed a wide range of factors to affect costs. Results: 42.1% of those treated only with oral agents, 66.1% of those treated with oral agents and insulin, and 57.2% of those treated with insulin alone were found to have suboptimal control (defined as fair or poor) throughout the study period (average duration of follow-up was 2.95 years). Results show that direct medical costs attributable to type 2 diabetes were 16% lower for individuals with good glycemic control than for those with fair control ($1,505 vs. $1,801, p < 0.05), and 20% lower for those with good glycemic control than for those with poor control ($1,505 vs. $1,871, p < 0.05). Prescription drug costs were also significantly lower for individuals with good glycemic control compared to those with fair ($377 vs. $465, p < 0.05) or poor control ($377 vs. $423, p < 0.05). Conclusion: Almost half (44%) of all patients diagnosed with type 2 diabetes are at sub-optimal glycemic control. Evidence from this analysis indicates that the direct medical costs of treating type 2 diabetes are significantly higher for individuals who have fair or poor glycemic control than for those who have good glycemic control. Patients under fair control account for a greater proportion of the cost burden associated with antidiabetic prescription drugs.

1 February 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
Abdullah BalkhairAbdullah Balkhair
Abdullah Balkhair
IAIbrahim Al-Zakwani
Ibrahim Al-Zakwani
MBM. Al Busaidi
M. Al Busaidi
AAA. Al-Khirbash
A. Al-Khirbash
SMS. Al Mubaihsi
S. Al Mubaihsi
OBO. Balkhair
O. Balkhair
The aim of this study was to evaluate the efficacy of anakinra in patients who were admitted to hospital for severe COVID-19 pneumonia requiring oxygen therapy. A prospective, open-label, interventional study in adults hospitalized with severe COVID-19 pneumonia was conducted. Patients in the interventional arm received subcutaneous anakinra (100 mg twice daily for 3 days, followed by 100 mg daily for 7 days) in addition to standard treatment. Main outcomes were the need for mechanical ventilation and in-hospital death. Secondary outcomes included successful weaning from supplemental oxygen and change in inflammatory biomarkers. Outcomes were compared with those of historical controls who had received standard treatment and supportive care. A total of 69 patients were included: 45 treated with anakinra and 24 historical controls. A need for mechanical ventilation occurred in 14 (31%) of the anakinra-treated group and 18 (75%) of the historical cohort (p < 0.001). In-hospital death occurred in 13 (29%) of the anakinra-treated group and 11 (46%) of the historical cohort (p = 0.082). Successful weaning from supplemental oxygen to ambient air was attained in 25 (63%) of the anakinra-treated group compared with 6 (27%) of the historical cohort (p = 0.008). Patients who received anakinra showed a significant reduction in inflammatory biomarkers. In patients with severe COVID-19 pneumonia and high oxygen requirement, anakinra could represent an effective treatment option and may confer clinical benefit. ISRCTN74727214.

1 January 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
FKFaryal khamis
Faryal khamis
HNHanan Al Naabi
Hanan Al Naabi
ALAdil Al Lawati
Adil Al Lawati
ZAZaiyana Ambusaidi
Zaiyana Ambusaidi
MSMariam Al Sharji
Mariam Al Sharji
IAIbrahim Al-Zakwani
Ibrahim Al-Zakwani
To evaluate the therapeutic effectiveness of favipiravir combined with inhaled interferon beta-1b in adult patients hospitalized with moderate to severe COVID-19 pneumonia. A randomized, open-label controlled trial of oral favipiravir in adults hospitalized with moderate to severe COVID-19 pneumonia from June 22nd 2020 to August 13th 2020 was conducted. Patients were randomly assigned to receive either a combination of favipiravir with interferon beta-1b by inhalation aerosol or hydroxychloroquine (HCQ). The outcome endpoints included improvement in inflammatory markers, lower length of hospital stay (LOS), discharges and lower overall 14-day mortality. A total of 89 patients underwent randomization with 49% (n = 44) assigned to favipiravir and 51% (n = 45) assigned HCQ. The overall mean age was 55 ± 14 years and 58% (n = 52) were males. There were no significant differences in the inflammatory biomarkers at hospital discharge between the two groups; C-reactive protein (p = 0.413), ferritin (p = 0.968), lactate dehydrogenase (p = 0.259) and interleukin 6 (p = 0.410). There were also no significant differences between the two groups with regards to the overall LOS (7 vs 7 days; p = 0.948), transfers to the ICU (18.2% vs 17.8%; p = 0.960), discharges (65.9% vs 68.9%; p = 0.764) and overall mortality (11.4% vs 13.3%; p = 0.778). No differences in clinical outcomes were found between favipiravir plus inhaled interferon beta-1b and hydroxychloroquine in adults hospitalized with moderate to severe COVID-19 pneumonia.

1 July 2011 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Open access
PDF file
MZMohammad Zubaid
Mohammad Zubaid
WRWafa A. Rashed
Wafa A. Rashed
AAAlawi A. Alsheikh-Ali
Alawi A. Alsheikh-Ali
WAWael AlMahmeed
Wael AlMahmeed
ASAbdullah Shehab
Abdullah Shehab
HAHaitham Amin
Haitham Amin
Background—Atrial fibrillation (AF) is the most common serious cardiac arrhythmia, and its prevalence is expected to increase. There is lack of data about patient characteristics, practice patterns, and outcomes of AF in the Arab Middle East. Methods and Results—The Gulf Survey of Atrial Fibrillation Events (Gulf SAFE) is a prospective, observational registry of patients with AF with a 12-month follow-up. The registry was emergency room based. Between October 2009 and June 2010, 2043 consecutive patients with AF were enrolled from 23 hospitals in 6 Middle Eastern Gulf countries. Data were collected on a standardized case report form and entered online. Data collected included patient demographics, medical history, type of AF, treatment, and outcome of emergency room visit. If patients were admitted, details of their treatment, investigations, and outcomes during hospital stay were collected. Completion of 12-month follow-up is expected by July 2011. The mean age was 57 years, and 52% were men. The most common concomitant condition was hypertension, present in 1072 (52%) patients. At enrollment, 28% of patients had a history of coronary artery disease, 30% had diabetes, and 16% had rheumatic valve disease. History of stroke and transient ischemic attacks were reported in 9% and 4% of patients, respectively. The most common type of AF, first attack AF, occurred in 37%, whereas 19% of patients had lone AF. Conclusions—Gulf SAFE will provide valuable insights into AF management and outcomes in the Gulf region of the Middle East.

17 July 2014 in Oman Medical Journal
Verified
Journal Article
Closed access
AAAhmed Al-Mandhari
Ahmed Al-Mandhari
IAIbrahim Al-Zakwani
Ibrahim Al-Zakwani
MAMoosa Al-Kindi
Moosa Al-Kindi
JTJihane Tawilah
Jihane Tawilah
ADAtsu S.S. Dorvlo
Atsu S.S. Dorvlo
Samir Al-AdawiSamir Al-Adawi
Samir Al-Adawi